CANNTAB THERAPEUTICS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.005 CAD | -.--% |
|
-.--% | -.--% |
| Apr. 15 | Canntab Therapeutics Limited announced that it expects to receive CAD 0.1 million in funding | CI |
| 2023 | Canntab Therapeutics Limited Provide an Update on Product Delivery | CI |
Valuation
| Fiscal Period: May | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Capitalization 1 | 20.81 | 18.47 | 32.1 | 36.3 | 11.48 |
| Enterprise Value (EV) 1 | 16.59 | 16.88 | 30.74 | 36.37 | 12.63 |
| P/E ratio | -7.46 x | -7.51 x | -10.2 x | -7.9 x | -3.02 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 780,440,057 x | 76,974,562 x | 240,767,156 x | - | 39,126,407 x |
| EV / Revenue | 622,272,659 x | 70,353,793 x | 230,537,065 x | - | 43,043,762 x |
| EV / EBITDA | -10.2 x | -8.45 x | -13.5 x | -11.3 x | -3.07 x |
| EV / FCF | -19,111,271 x | -13,143,595 x | -17,379,413 x | -18,254,708 x | -9,273,652 x |
| FCF Yield | -0% | -0% | -0% | -0% | -0% |
| Price to Book | 5 x | 8.15 x | 9.1 x | 16 x | -36.9 x |
| Nbr of stocks (in thousands) | 24,485 | 25,307 | 32,758 | 35,938 | 38,909 |
| Reference price 2 | 0.8500 | 0.7300 | 0.9800 | 1.010 | 0.2950 |
| Announcement Date | 9/28/18 | 9/30/19 | 9/28/20 | 9/28/21 | 9/28/22 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: May | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales | - | 0.0267 | 0.24 | 0.1333 | - | 0.2934 |
| EBITDA 1 | -1.115 | -1.629 | -1.998 | -2.269 | -3.212 | -4.114 |
| EBIT 1 | -1.116 | -1.681 | -2.079 | -2.447 | -3.594 | -4.606 |
| Operating Margin | - | -6,303.01% | -866.08% | -1,835.39% | - | -1,570.01% |
| Earnings before Tax (EBT) 1 | -1.116 | -2.408 | -2.459 | -2.607 | -4.42 | -3.689 |
| Net income 1 | -1.116 | -2.408 | -2.459 | -2.607 | -4.42 | -3.689 |
| Net margin | - | -9,031.44% | -1,024.41% | -1,955.42% | - | -1,257.55% |
| EPS 2 | -0.2980 | -0.1140 | -0.0972 | -0.0960 | -0.1279 | -0.0978 |
| Free Cash Flow | - | -0.8683 | -1.285 | -1.769 | -1.993 | -1.362 |
| FCF margin | - | -3,256.05% | -535.27% | -1,326.5% | - | -464.15% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/19/18 | 9/28/18 | 9/30/19 | 9/28/20 | 9/28/21 | 9/28/22 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: May | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 0.08 | 1.15 |
| Net Cash position 1 | 0.96 | 4.22 | 1.59 | 1.36 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.0234 x | -0.2793 x |
| Free Cash Flow | - | -0.87 | -1.28 | -1.77 | -1.99 | -1.36 |
| ROE (net income / shareholders' equity) | - | -90.2% | -74.8% | -90% | -152% | -377% |
| ROA (Net income/ Total Assets) | - | -35.7% | -35.4% | -37.8% | -37.8% | -62.5% |
| Assets 1 | - | 6.748 | 6.948 | 6.906 | 11.68 | 5.904 |
| Book Value Per Share 2 | 0.2200 | 0.1700 | 0.0900 | 0.1100 | 0.0600 | -0.0100 |
| Cash Flow per Share 2 | 0.2000 | 0.1700 | 0.0200 | 0.0600 | 0.0400 | 0.0200 |
| Capex 1 | 0.1 | 0.11 | 0.25 | 0.79 | 0.27 | 0.03 |
| Capex / Sales | - | 398.18% | 104.15% | 593.35% | - | 10.26% |
| Announcement Date | 4/19/18 | 9/28/18 | 9/30/19 | 9/28/20 | 9/28/21 | 9/28/22 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 142K | |
| -15.13% | 4.51B | |
| -9.75% | 3.15B | |
| +2.14% | 3.1B | |
| -6.82% | 2.42B | |
| +47.87% | 1.97B | |
| +0.09% | 1.65B | |
| -7.89% | 1.68B | |
| -12.97% | 1.53B | |
| +33.40% | 1.38B |
- Stock Market
- Equities
- PILL Stock
- Financials Canntab Therapeutics Limited
